Analysis of Solvency Ratios
Quarterly Data
Solvency ratios also known as long-term debt ratios measure a company’s ability to meet long-term obligations.
Solvency Ratios (Summary)
Stryker Corp., solvency ratios (quarterly data)
Based on: 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-06), 10-Q (filing date: 2019-10-30), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-22), 10-Q (filing date: 2016-04-22), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-10-23), 10-Q (filing date: 2015-07-29), 10-Q (filing date: 2015-04-30).
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Stryker Corp.’s debt to equity ratio deteriorated from Q1 2020 to Q2 2020 but then slightly improved from Q2 2020 to Q3 2020. |
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Stryker Corp.’s debt to capital ratio deteriorated from Q1 2020 to Q2 2020 but then slightly improved from Q2 2020 to Q3 2020. |
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Stryker Corp.’s debt to assets ratio deteriorated from Q1 2020 to Q2 2020 but then slightly improved from Q2 2020 to Q3 2020. |
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Stryker Corp.’s financial leverage ratio increased from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
Debt to Equity
Stryker Corp., debt to equity calculation (quarterly data)
Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Current maturities of debt | 1,119 | 1,110 | 1,103 | 859 | 526 | 539 | 521 | 1,373 | 1,275 | 1,277 | 1,984 | 632 | 632 | 774 | 35 | 228 | 135 | 927 | 770 | 769 | 971 | 227 | 225 | |||||||
Long-term debt, excluding current maturities | 12,008 | 11,811 | 9,404 | 10,231 | 7,889 | 7,974 | 7,950 | 8,486 | 5,928 | 5,925 | 5,920 | 6,590 | 6,593 | 6,592 | 7,184 | 6,686 | 6,713 | 6,717 | 6,706 | 3,253 | 2,511 | 3,242 | 3,257 | |||||||
Total debt | 13,127 | 12,921 | 10,507 | 11,090 | 8,415 | 8,513 | 8,471 | 9,859 | 7,203 | 7,202 | 7,904 | 7,222 | 7,225 | 7,366 | 7,219 | 6,914 | 6,848 | 7,644 | 7,476 | 4,022 | 3,482 | 3,469 | 3,482 | |||||||
Total Stryker shareholders’ equity | 12,986 | 12,754 | 13,115 | 12,807 | 12,315 | 11,943 | 11,693 | 11,730 | 9,860 | 9,460 | 9,214 | 9,966 | 10,425 | 10,035 | 9,704 | 9,550 | 9,332 | 9,098 | 8,808 | 8,511 | 8,484 | 8,505 | 8,321 | |||||||
Solvency Ratio | ||||||||||||||||||||||||||||||
Debt to equity1 | 1.01 | 1.01 | 0.80 | 0.87 | 0.68 | 0.71 | 0.72 | 0.84 | 0.73 | 0.76 | 0.86 | 0.72 | 0.69 | 0.73 | 0.74 | 0.72 | 0.73 | 0.84 | 0.85 | 0.47 | 0.41 | 0.41 | 0.42 | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Debt to Equity, Competitors2 | ||||||||||||||||||||||||||||||
Becton, Dickinson & Co. | 0.78 | 1.01 | 0.92 | 0.92 | 0.94 | 0.97 | 0.98 | 1.02 | 1.04 | 1.08 | 1.07 | 1.46 | 1.51 | 1.29 | 1.45 | 1.51 | 1.48 | 1.63 | 1.77 | 1.79 | 1.82 | 1.93 | 2.00 | |||||||
Boston Scientific Corp. | 0.60 | 0.61 | 0.75 | 0.72 | 1.12 | 1.01 | 1.00 | 0.81 | 0.80 | 0.84 | 0.82 | 0.80 | 0.75 | 0.81 | 0.78 | 0.81 | 0.84 | 0.87 | 0.88 | 0.90 | 0.91 | 0.78 | 0.66 | |||||||
Danaher Corp. | 0.57 | 0.62 | 0.84 | 0.72 | 0.54 | 0.32 | 0.30 | 0.35 | 0.38 | 0.42 | 0.39 | 0.40 | 0.43 | 0.47 | 0.50 | 0.53 | 0.36 | 0.59 | 0.51 | 0.54 | 0.65 | 0.13 | 0.14 | |||||||
Edwards Lifesciences Corp. | 0.14 | 0.15 | 0.15 | 0.14 | 0.16 | 0.17 | 0.17 | 0.19 | 0.36 | 0.38 | 0.32 | 0.35 | 0.33 | 0.35 | 0.31 | 0.31 | 0.22 | 0.24 | 0.26 | 0.24 | 0.25 | 0.26 | 0.27 | |||||||
Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
Medtronic PLC | 0.49 | 0.51 | 0.52 | 0.51 | 0.50 | 0.50 | 0.50 | 0.51 | 0.57 | 0.56 | 0.67 | 0.66 | 0.65 | 0.65 | 0.63 | 0.60 | 0.71 | 0.69 | 0.67 | 0.68 | 1.43 | 0.70 | 0.67 | |||||||
Thermo Fisher Scientific Inc. | 0.66 | 0.71 | 0.70 | 0.60 | 0.58 | 0.66 | 0.66 | 0.69 | 0.70 | 0.73 | 0.80 | 0.83 | 0.89 | 0.75 | 0.78 | 0.77 | 0.87 | 0.67 | 0.72 | 0.59 | 0.64 | 0.68 | 0.75 | |||||||
UnitedHealth Group Inc. | 0.67 | 0.72 | 0.91 | 0.71 | 0.82 | 0.80 | 0.74 | 0.71 | 0.67 | 0.73 | 0.75 | 0.66 | 0.65 | 0.74 | 0.81 | 0.86 | 0.88 | 0.91 | 0.96 | 0.95 | 0.96 | 0.55 | 0.58 |
Based on: 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-06), 10-Q (filing date: 2019-10-30), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-22), 10-Q (filing date: 2016-04-22), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-10-23), 10-Q (filing date: 2015-07-29), 10-Q (filing date: 2015-04-30).
1 Q3 2020 Calculation
Debt to equity = Total debt ÷ Total Stryker shareholders’ equity
= 13,127 ÷ 12,986 = 1.01
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Stryker Corp.’s debt to equity ratio deteriorated from Q1 2020 to Q2 2020 but then slightly improved from Q2 2020 to Q3 2020. |
Debt to Capital
Stryker Corp., debt to capital calculation (quarterly data)
Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Current maturities of debt | 1,119 | 1,110 | 1,103 | 859 | 526 | 539 | 521 | 1,373 | 1,275 | 1,277 | 1,984 | 632 | 632 | 774 | 35 | 228 | 135 | 927 | 770 | 769 | 971 | 227 | 225 | |||||||
Long-term debt, excluding current maturities | 12,008 | 11,811 | 9,404 | 10,231 | 7,889 | 7,974 | 7,950 | 8,486 | 5,928 | 5,925 | 5,920 | 6,590 | 6,593 | 6,592 | 7,184 | 6,686 | 6,713 | 6,717 | 6,706 | 3,253 | 2,511 | 3,242 | 3,257 | |||||||
Total debt | 13,127 | 12,921 | 10,507 | 11,090 | 8,415 | 8,513 | 8,471 | 9,859 | 7,203 | 7,202 | 7,904 | 7,222 | 7,225 | 7,366 | 7,219 | 6,914 | 6,848 | 7,644 | 7,476 | 4,022 | 3,482 | 3,469 | 3,482 | |||||||
Total Stryker shareholders’ equity | 12,986 | 12,754 | 13,115 | 12,807 | 12,315 | 11,943 | 11,693 | 11,730 | 9,860 | 9,460 | 9,214 | 9,966 | 10,425 | 10,035 | 9,704 | 9,550 | 9,332 | 9,098 | 8,808 | 8,511 | 8,484 | 8,505 | 8,321 | |||||||
Total capital | 26,113 | 25,675 | 23,622 | 23,897 | 20,730 | 20,456 | 20,164 | 21,589 | 17,063 | 16,662 | 17,118 | 17,188 | 17,650 | 17,401 | 16,923 | 16,464 | 16,180 | 16,742 | 16,284 | 12,533 | 11,966 | 11,974 | 11,803 | |||||||
Solvency Ratio | ||||||||||||||||||||||||||||||
Debt to capital1 | 0.50 | 0.50 | 0.44 | 0.46 | 0.41 | 0.42 | 0.42 | 0.46 | 0.42 | 0.43 | 0.46 | 0.42 | 0.41 | 0.42 | 0.43 | 0.42 | 0.42 | 0.46 | 0.46 | 0.32 | 0.29 | 0.29 | 0.30 | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Debt to Capital, Competitors2 | ||||||||||||||||||||||||||||||
Becton, Dickinson & Co. | 0.44 | 0.50 | 0.48 | 0.48 | 0.48 | 0.49 | 0.50 | 0.51 | 0.51 | 0.52 | 0.52 | 0.59 | 0.60 | 0.56 | 0.59 | 0.60 | 0.60 | 0.62 | 0.64 | 0.64 | 0.64 | 0.66 | 0.67 | |||||||
Boston Scientific Corp. | 0.37 | 0.38 | 0.43 | 0.42 | 0.53 | 0.50 | 0.50 | 0.45 | 0.44 | 0.46 | 0.45 | 0.44 | 0.43 | 0.45 | 0.44 | 0.45 | 0.46 | 0.47 | 0.47 | 0.47 | 0.48 | 0.44 | 0.40 | |||||||
Danaher Corp. | 0.37 | 0.38 | 0.46 | 0.42 | 0.35 | 0.24 | 0.23 | 0.26 | 0.28 | 0.29 | 0.28 | 0.29 | 0.30 | 0.32 | 0.33 | 0.35 | 0.26 | 0.37 | 0.34 | 0.35 | 0.39 | 0.12 | 0.12 | |||||||
Edwards Lifesciences Corp. | 0.12 | 0.13 | 0.13 | 0.13 | 0.13 | 0.15 | 0.15 | 0.16 | 0.26 | 0.27 | 0.25 | 0.26 | 0.25 | 0.26 | 0.24 | 0.24 | 0.18 | 0.20 | 0.21 | 0.19 | 0.20 | 0.21 | 0.21 | |||||||
Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
Medtronic PLC | 0.33 | 0.34 | 0.34 | 0.34 | 0.33 | 0.34 | 0.33 | 0.34 | 0.36 | 0.36 | 0.40 | 0.40 | 0.39 | 0.39 | 0.39 | 0.38 | 0.41 | 0.41 | 0.40 | 0.40 | 0.59 | 0.41 | 0.40 | |||||||
Thermo Fisher Scientific Inc. | 0.40 | 0.42 | 0.41 | 0.37 | 0.37 | 0.40 | 0.40 | 0.41 | 0.41 | 0.42 | 0.44 | 0.45 | 0.47 | 0.43 | 0.44 | 0.44 | 0.47 | 0.40 | 0.42 | 0.37 | 0.39 | 0.40 | 0.43 | |||||||
UnitedHealth Group Inc. | 0.40 | 0.42 | 0.48 | 0.41 | 0.45 | 0.44 | 0.43 | 0.41 | 0.40 | 0.42 | 0.43 | 0.40 | 0.39 | 0.43 | 0.45 | 0.46 | 0.47 | 0.48 | 0.49 | 0.49 | 0.49 | 0.35 | 0.37 |
Based on: 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-06), 10-Q (filing date: 2019-10-30), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-22), 10-Q (filing date: 2016-04-22), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-10-23), 10-Q (filing date: 2015-07-29), 10-Q (filing date: 2015-04-30).
1 Q3 2020 Calculation
Debt to capital = Total debt ÷ Total capital
= 13,127 ÷ 26,113 = 0.50
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Stryker Corp.’s debt to capital ratio deteriorated from Q1 2020 to Q2 2020 but then slightly improved from Q2 2020 to Q3 2020. |
Debt to Assets
Stryker Corp., debt to assets calculation (quarterly data)
Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Current maturities of debt | 1,119 | 1,110 | 1,103 | 859 | 526 | 539 | 521 | 1,373 | 1,275 | 1,277 | 1,984 | 632 | 632 | 774 | 35 | 228 | 135 | 927 | 770 | 769 | 971 | 227 | 225 | |||||||
Long-term debt, excluding current maturities | 12,008 | 11,811 | 9,404 | 10,231 | 7,889 | 7,974 | 7,950 | 8,486 | 5,928 | 5,925 | 5,920 | 6,590 | 6,593 | 6,592 | 7,184 | 6,686 | 6,713 | 6,717 | 6,706 | 3,253 | 2,511 | 3,242 | 3,257 | |||||||
Total debt | 13,127 | 12,921 | 10,507 | 11,090 | 8,415 | 8,513 | 8,471 | 9,859 | 7,203 | 7,202 | 7,904 | 7,222 | 7,225 | 7,366 | 7,219 | 6,914 | 6,848 | 7,644 | 7,476 | 4,022 | 3,482 | 3,469 | 3,482 | |||||||
Total assets | 32,286 | 31,483 | 29,440 | 30,167 | 26,659 | 26,354 | 25,937 | 27,229 | 22,084 | 21,570 | 22,133 | 22,197 | 21,485 | 21,292 | 20,517 | 20,435 | 20,187 | 20,520 | 19,668 | 16,247 | 15,917 | 16,819 | 16,580 | |||||||
Solvency Ratio | ||||||||||||||||||||||||||||||
Debt to assets1 | 0.41 | 0.41 | 0.36 | 0.37 | 0.32 | 0.32 | 0.33 | 0.36 | 0.33 | 0.33 | 0.36 | 0.33 | 0.34 | 0.35 | 0.35 | 0.34 | 0.34 | 0.37 | 0.38 | 0.25 | 0.22 | 0.21 | 0.21 | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Debt to Assets, Competitors2 | ||||||||||||||||||||||||||||||
Becton, Dickinson & Co. | 0.35 | 0.40 | 0.37 | 0.37 | 0.39 | 0.39 | 0.40 | 0.40 | 0.41 | 0.42 | 0.41 | 0.50 | 0.51 | 0.43 | 0.45 | 0.45 | 0.46 | 0.48 | 0.49 | 0.48 | 0.49 | 0.49 | 0.55 | |||||||
Boston Scientific Corp. | 0.30 | 0.31 | 0.34 | 0.33 | 0.41 | 0.39 | 0.39 | 0.34 | 0.33 | 0.33 | 0.30 | 0.29 | 0.30 | 0.32 | 0.31 | 0.30 | 0.31 | 0.30 | 0.32 | 0.31 | 0.32 | 0.30 | 0.26 | |||||||
Danaher Corp. | 0.30 | 0.31 | 0.38 | 0.35 | 0.29 | 0.19 | 0.18 | 0.20 | 0.22 | 0.24 | 0.22 | 0.23 | 0.24 | 0.25 | 0.26 | 0.27 | 0.20 | 0.28 | 0.26 | 0.27 | 0.30 | 0.09 | 0.09 | |||||||
Edwards Lifesciences Corp. | 0.09 | 0.09 | 0.10 | 0.09 | 0.10 | 0.11 | 0.11 | 0.11 | 0.20 | 0.21 | 0.18 | 0.18 | 0.19 | 0.20 | 0.18 | 0.18 | 0.14 | 0.15 | 0.16 | 0.15 | 0.16 | 0.17 | 0.17 | |||||||
Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
Medtronic PLC | 0.28 | 0.28 | 0.29 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.30 | 0.31 | 0.34 | 0.34 | 0.33 | 0.33 | 0.33 | 0.31 | 0.35 | 0.34 | 0.34 | 0.34 | 0.52 | 0.35 | 0.34 | |||||||
Thermo Fisher Scientific Inc. | 0.33 | 0.35 | 0.34 | 0.30 | 0.30 | 0.33 | 0.33 | 0.34 | 0.34 | 0.35 | 0.37 | 0.37 | 0.39 | 0.36 | 0.37 | 0.36 | 0.39 | 0.33 | 0.35 | 0.31 | 0.32 | 0.34 | 0.35 | |||||||
UnitedHealth Group Inc. | 0.23 | 0.24 | 0.27 | 0.23 | 0.26 | 0.25 | 0.24 | 0.24 | 0.22 | 0.23 | 0.23 | 0.23 | 0.21 | 0.23 | 0.25 | 0.27 | 0.27 | 0.28 | 0.29 | 0.29 | 0.29 | 0.20 | 0.20 |
Based on: 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-06), 10-Q (filing date: 2019-10-30), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-22), 10-Q (filing date: 2016-04-22), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-10-23), 10-Q (filing date: 2015-07-29), 10-Q (filing date: 2015-04-30).
1 Q3 2020 Calculation
Debt to assets = Total debt ÷ Total assets
= 13,127 ÷ 32,286 = 0.41
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Stryker Corp.’s debt to assets ratio deteriorated from Q1 2020 to Q2 2020 but then slightly improved from Q2 2020 to Q3 2020. |
Financial Leverage
Stryker Corp., financial leverage calculation (quarterly data)
Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Total assets | 32,286 | 31,483 | 29,440 | 30,167 | 26,659 | 26,354 | 25,937 | 27,229 | 22,084 | 21,570 | 22,133 | 22,197 | 21,485 | 21,292 | 20,517 | 20,435 | 20,187 | 20,520 | 19,668 | 16,247 | 15,917 | 16,819 | 16,580 | |||||||
Total Stryker shareholders’ equity | 12,986 | 12,754 | 13,115 | 12,807 | 12,315 | 11,943 | 11,693 | 11,730 | 9,860 | 9,460 | 9,214 | 9,966 | 10,425 | 10,035 | 9,704 | 9,550 | 9,332 | 9,098 | 8,808 | 8,511 | 8,484 | 8,505 | 8,321 | |||||||
Solvency Ratio | ||||||||||||||||||||||||||||||
Financial leverage1 | 2.49 | 2.47 | 2.24 | 2.36 | 2.16 | 2.21 | 2.22 | 2.32 | 2.24 | 2.28 | 2.40 | 2.23 | 2.06 | 2.12 | 2.11 | 2.14 | 2.16 | 2.26 | 2.23 | 1.91 | 1.88 | 1.98 | 1.99 | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Financial Leverage, Competitors2 | ||||||||||||||||||||||||||||||
Becton, Dickinson & Co. | 2.25 | 2.55 | 2.45 | 2.46 | 2.43 | 2.47 | 2.47 | 2.57 | 2.53 | 2.58 | 2.61 | 2.91 | 2.95 | 3.03 | 3.21 | 3.35 | 3.24 | 3.42 | 3.61 | 3.74 | 3.73 | 3.95 | 3.65 | |||||||
Boston Scientific Corp. | 1.98 | 1.97 | 2.18 | 2.20 | 2.76 | 2.58 | 2.58 | 2.41 | 2.46 | 2.53 | 2.73 | 2.72 | 2.46 | 2.54 | 2.54 | 2.69 | 2.73 | 2.87 | 2.74 | 2.87 | 2.84 | 2.60 | 2.53 | |||||||
Danaher Corp. | 1.92 | 1.97 | 2.22 | 2.05 | 1.89 | 1.66 | 1.64 | 1.70 | 1.72 | 1.77 | 1.73 | 1.77 | 1.81 | 1.86 | 1.90 | 1.97 | 1.78 | 2.06 | 1.97 | 2.04 | 2.15 | 1.53 | 1.55 | |||||||
Edwards Lifesciences Corp. | 1.62 | 1.67 | 1.56 | 1.56 | 1.56 | 1.59 | 1.59 | 1.70 | 1.77 | 1.80 | 1.79 | 1.93 | 1.74 | 1.75 | 1.74 | 1.72 | 1.61 | 1.64 | 1.68 | 1.62 | 1.60 | 1.58 | 1.58 | |||||||
Intuitive Surgical Inc. | 1.15 | 1.16 | 1.16 | 1.18 | 1.18 | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 | 1.22 | 1.14 | 1.16 | 1.16 | 1.12 | 1.11 | 1.12 | 1.12 | 1.14 | 1.14 | 1.15 | 1.15 | |||||||
Medtronic PLC | 1.79 | 1.80 | 1.81 | 1.79 | 1.78 | 1.78 | 1.79 | 1.80 | 1.91 | 1.84 | 1.98 | 1.98 | 1.98 | 1.96 | 1.94 | 1.92 | 2.02 | 2.01 | 1.98 | 2.00 | 2.74 | 2.00 | 1.95 | |||||||
Thermo Fisher Scientific Inc. | 2.01 | 2.06 | 2.05 | 1.97 | 1.93 | 2.02 | 2.01 | 2.04 | 2.05 | 2.10 | 2.17 | 2.23 | 2.27 | 2.08 | 2.12 | 2.13 | 2.22 | 1.99 | 2.05 | 1.92 | 1.97 | 2.02 | 2.10 | |||||||
UnitedHealth Group Inc. | 2.93 | 3.03 | 3.32 | 3.02 | 3.16 | 3.15 | 3.12 | 2.94 | 3.02 | 3.20 | 3.27 | 2.91 | 3.10 | 3.20 | 3.27 | 3.21 | 3.28 | 3.29 | 3.35 | 3.29 | 3.27 | 2.77 | 2.81 |
Based on: 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-06), 10-Q (filing date: 2019-10-30), 10-Q (filing date: 2019-07-26), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-10-26), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-22), 10-Q (filing date: 2016-04-22), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-10-23), 10-Q (filing date: 2015-07-29), 10-Q (filing date: 2015-04-30).
1 Q3 2020 Calculation
Financial leverage = Total assets ÷ Total Stryker shareholders’ equity
= 32,286 ÷ 12,986 = 2.49
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Stryker Corp.’s financial leverage ratio increased from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |